- Research Article
- 10.1055/s-0046-1816502
Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results
- Mar 01, 2026
- Pneumologie
- C Vogelmeier + 9 more +9
Publications from 2021 to 2026
Showing 10 of 47 papers
Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results
Adjudicating Muslimness: Islamophobia and the Limits of Swedish Law
Since the late 2010s, Swedish Muslim civil society has pivoted from conventional political contention to courtroom strategies to contest Islamophobia. This article asks why, if courts are imagined as neutral rights-protecting forums, litigation has so often produced losses that normalize contested practices, from funding denials and “neutrality” bans on hijab to the permissibility of Qur’an burnings and closures of Muslim schools. We analyze four “Muslim cases” across administrative, civil, and criminal law and show how adjudication frequently effaces Islamophobia’s structural character by translating claims into individualized legal boxes: religion, ethnicity, public order, or offender motive. Drawing on Critical Legal Studies and Critical Race Theory, we trace three misfits in Swedish law: fragmented normative coverage (e.g., “ethnicity” replacing “race,” “religion” undefined), a motive-centric hate-crime design with thin guidance, and broad judicial discretion that invites common-sense heuristics. These features, interacting with securitizing social imaginaries, render evidence of racialized anti-Muslim harm legally illegible, producing outcomes that appear neutral yet substantively disadvantage Muslims. Conceptually, we theorize how courts’ individualizing grammar depoliticizes structurally produced harms; empirically, we map recurring interpretive moves that sideline Muslimness. Normatively, we outline context-sensitive doctrinal and procedural adjustments—treating Islamophobia as a key contextual factor in proportionality, sharpening evidentiary standards for motive, and recalibrating indirect discrimination toward accommodation.
Read moreEvaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.
Clinical remission (CR) is an emerging treatment goal in asthma. However, evidence showing whether CR is achievable with inhaled therapy is lacking. This post hoc analysis of CAPTAIN evaluated attainability of a composite CR endpoint with inhaled fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or FF/VI. CAPTAIN (GSK 205715) was a Phase IIIA, randomized, controlled, 24-52-week trial comparing once-daily single-inhaler FF/UMEC/VI versus FF/VI in adults with uncontrolled moderate-to-severe asthma despite ICS/LABA. CR was defined as a composite endpoint comprising no systemic corticosteroids, no severe exacerbations, ACQ-5 total score < 1.50, and either change from baseline in FEV1 ≥ 0ml (lung function stabilization) or ≥ 100ml (lung function optimization), assessed for patients meeting the CR endpoint at Week 24 (W24) and achieving CR at W52 with FF/UMEC/VI (100/62.5/25, 200/62.5/25μg) versus FF/VI (100/25, 200/25μg). Additional analyses assessed the CR endpoint at W24/W52 using ACQ-5 ≤ 0.75 and ≤ 1.00 thresholds. Adjusted odds/risk ratios for CR were calculated for W24. More patients met the CR endpoint (lung function stabilization/optimization) with FF/UMEC/VI versus FF/VI at W24 (stabilization: 42-47% vs 31-36%; optimization: 31-36% vs 19-26%) and W52 (stabilization: 43-47% vs 33-34%; optimization: 30-38% vs 21-24%). Using more stringent ACQ-5 thresholds, fewer patients met the CR endpoint with ACQ ≤ 0.75 versus < 1.50 across treatment arms and timepoints. The odds and probability of meeting the CR endpoint versus not meeting the CR endpoint at W24 were greater with FF/UMEC/VI versus FF/VI, regardless of FF dose. The results of this post hoc analysis demonstrate that CR is achievable with inhaled therapy in moderate-to-severe asthma and is more likely with FF/UMEC/VI than FF/VI. CR should be considered an attainable treatment goal for patients with asthma, irrespective of disease severity or treatment history. ClinialTrials.gov identifier, NCT02924688.
Read moreS164 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma, independent of baseline IgE and FeNO in the real world: 2-year results from REALITI-A
<h3></h3> Introduction and objectives: REALITI-A study demonstrated mepolizumab effectiveness independent of immunoglobulin-E (IgE) and fractional exhaled nitric oxide (FeNO) levels in patients with severe asthma in preliminary 1-year analyses. However, additional longer-term real-world evidence on the effect of mepolizumab on asthma control and lung function may be useful to inform clinical decision making. <h3>Method</h3> REALITI-A, a 2-year, observational, prospective study enrolled patients (≥18 years) with severe asthma, newly prescribed mepolizumab (100-mg subcutaneously). Changes from baseline in asthma control (Asthma Control Questionnaire-5 [ACQ-5] scores, minimal clinically important difference: 0.5) and lung function (forced expiratory volume in 1 second [FEV<sub>1</sub>]) were assessed for baseline FeNO subgroups (<25, 25–50, ≥50 parts per billion [ppb]) and baseline IgE subgroups (<60, 60–<180, 180–<500, ≥500 KU/L) at 1-year and 2-years post-mepolizumab exposure. <h3>Results</h3> ACQ-5 scores decreased across all FeNO subgroups 1-year post-mepolizumab exposure and were sustained at 2-years: <25 ppb (least squares [LS] mean change from baseline [95% CI]: -1.21 [-1.58, -0.85]), 25–<50 ppb ( -1.68 [-2.10, -1.25]), ≥50 ppb (-1.61 [-1.89, -1.34]; figure 1). ACQ-5 scores also decreased across all IgE subgroups at 1-year and were sustained at 2-years: <60 KU/L (-1.53 [-1.82, -1.24]), 60–<180 KU/L (-1.59 [-1.90, -1.27]), 180–<500 KU/L (-1.64 [-1.96, -1.31]), ≥500 KU/L (-1.19 [-1.53, -0.84]). FEV<sub>1</sub> improved at Months 9–12 post-mepolizumab exposure for FeNO <25 ppb and ≥50 ppb subgroups and was sustained at Months 21–24 (LS mean change from baseline [95% CI]: 133.1 [22.7, 243.6]; 220.6 [98.0, 343.2], respectively). FEV<sub>1</sub> also improved at Months 9–12 post-mepolizumab exposure for IgE <60 KU/L, 60–<180 KU/L and 180–<500 KU/L, and was sustained at Months 21–24 (LS mean change from baseline [95% CI]: 167.6 [81.1, 254.1], 108.8 [-31.7, 249.3], 198.1 [107.7, 288.6], respectively). FEV<sub>1</sub> improvements were seen to a lesser extent in FeNO 25–<50 ppb subgroup at 2-years (72.2 [-57.6, 202.1]) and IgE ≥500 KU/L subgroup at Months 21–24 (82.0 [-60.7, 224.8]). <h3>Conclusion</h3> Treatment with mepolizumab in a real-life setting improves asthma control and lung function after 1-year, with improvements sustained to 2-years, independent of baseline FeNO and IgE. <h3>Funding</h3> GSK (204710).
Read moreAcademic Terminology
Impact of Simultaneous Step-Up to High-Dose Fluticasone Furoate and Addition of Umeclidinium on a Clinical Remission Endpoint in Asthma: CAPTAIN Post Hoc Analysis
Abstract Rationale: Clinical remission (CR) is an ambitious and achievable treatment goal in asthma. There is no standardized CR definition; national guidelines and international recommendations assess CR after 52 weeks of treatment with four key components: i) no severe exacerbations; ii) no systemic corticosteroids; iii) asthma control; iv) stable/optimized lung function. Previous post hoc analyses of the CAPTAIN trial demonstrated that patients with uncontrolled moderate-to-severe asthma not yet considered for biologics can achieve CR with both fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and FF/VI inhaled maintenance therapies. We assessed the attainability of CR in patients taking FF/VI 200/25, FF/UMEC/VI 100/62.5/25, or FF/UMEC/VI 200/62.5/25 versus FF/VI 100/25. Methods: The CAPTAIN Phase 3 trial assessed FF/UMEC/VI versus FF/VI in terms of lung function, asthma control, and exacerbations in patients with uncontrolled moderate-to-severe asthma despite inhaled corticosteroid/long-acting β2-agonist maintenance therapy. In this post hoc analysis, the proportion and odds of patients meeting a composite CR endpoint (oral corticosteroid free, no severe exacerbations, Asthma Control Questionnaire 5-item total score &lt;1.5, change from baseline in forced expiratory volume in 1 second ≥100 mL) were assessed at Week 24 in patients taking FF 200 mcg and adding UMEC to FF/VI (simultaneous step-up) versus FF 100 mcg and dual therapy. Results: With FF/VI 100/25, 19% of patients (n=77/407) met the CR endpoint at Week 24; 26% (n=104/406) met the CR endpoint with increased FF dose (FF/VI 200/25), 31% (n=127/406) when adding UMEC (FF/UMEC/VI 100/62.5/25), and 36% (n=146/408) with simultaneous step-up (FF/UMEC/VI 200/62.5/25). Compared with FF/VI 100/25, odds of meeting the CR endpoint at Week 24 were greater with increased FF dose (FF/VI 200/25: odds ratio [95% confidence interval]: 1.51 [1.08, 2.11], p=0.017) or with addition of UMEC (FF/UMEC/VI 100/62.5/25: 1.93 [1.39, 2.68], p&lt;0.001). The greatest odds of meeting the CR endpoint at Week 24 were obtained with simultaneous step-up (FF/UMEC/VI 200/62.5/25: 2.44 [1.76, 3.37], p&lt;0.001) (Figure). P-values are nominally statistically significant. Conclusions: Both increasing FF dose and adding UMEC contributed to improving clinical outcomes in patients with asthma. These results suggest that the greater odds of meeting the CR endpoint with FF/UMEC/VI 200/62.5/25 versus FF/VI 100/25 were mostly driven by the addition of UMEC. Although data over 52 weeks are needed to confirm achievement of CR, patients not yet considered for biologics with moderate-to-severe asthma uncontrolled on FF/VI 100/25 may gain greater benefits with simultaneous step-up to high-dose triple therapy versus increasing FF dose or adding UMEC alone.
Read moreKetenen van het verleden
Chains of the past. The long road to awareness of the Dutch slavery past and its impact in today’s society In recent years, there has been increasing attention for the slavery past. For a long time this part of our past was neglected and a public debate was not possible. The national history was mainly written from the perspective of the glorious days of the Golden Age. Only in the recent decades more attention has been paid to acknowledging the dark sides of our national past. It is becoming increasingly clear that slavery, the slavery trade and forced deportations still make deep scars into today’s society. Ignoring this will complicate healing. Recognition and being able to discuss the slavery past may contribute to healing. Recent national and international developments, such as the Black Lives Matter movement and the public debate that followed this by a larger public than the communities of descendants who were fighting for recognition and excuses for a long time, contributed to the willingness of the government to give more attention to the active role the Netherlands played in the transatlantic slave trade. In this article the authors discuss the assignment that the Minister of Internal Affairs gave the Advisory Board Dialogue Group on the Slavery Past, that is to advise which measures should be taken to further healing and reparations for the slavery past. Which measures are necessary to come to a meaningful debate about that shared past? The advised measures given in the report Chains of the past are focused on three central terms: recognition, reparations and excuses.
Read moreOutbreak of shoot blight and dieback of <i>Eucalyptus</i> spp., caused by <i>Pseudoplagiostoma eucalypti</i> in Brazil
Abstract An outbreak of a new and severe disease was observed in Eucalyptus plantations of Bahia state, Brazil. An Ascomycota fungus has been frequently associated with the main symptoms of the disease namely leaf spot, branch cankers, shoot blight, defoliation, and dieback. Based on morphological characteristics, phylogenetic analysis (ITS and TEF‐1α genes), and pathogenicity test on Eucalyptus plants, Pseudoplagiostoma eucalypti was identified as the causal agent of the disease. Although P. eucalytpi has been known from in Brazil since 1998, this is the first report of it causing severe disease and die‐back on Eucalyptus spp. and we also record new symptoms associated with the pathogen.
Read moreLa prévention de l’apatridie dans le système africain des droits de l’homme
RÉSUMÉ:
 L’apatridie n’est pas un phénomène nouveau en Afrique. Cependant, il a pris des tournures inquiétantes ces dernières années. Cette contribution questionne l’apport des normes juridiques du système africain des droits de l’homme dans la prévention de l’apatridie. L’analyse se base fondamentalement sur la Charte africaine des droits de l’homme et des peuples, ses instruments connexes et la pratique de la Commission et de la Cour africaines des droits de l’homme et des peuples. L’article aboutie à deux résultats. D’abord, il constate que l’arsenal normatif en matière de prévention de l’apatridie en Afrique n’est pas totalement satisfaisant. Ensuite, il démontre que la Cour et la Commission de par leurs jurisprudences, jouent un rôle important dans la prévention du phénomène. En vue d’une protection étanche à l’avenir, l’auteur propose d’une part, l’adoption et l’entrée en vigueur imminente du protocole à la Charte africaine sur les aspects spécifiques du droit à la nationalité et l’éradication de l’apatridie en Afrique, d’autre part, l’érection des garanties au plan national contre l’apatridie et le respect des décisions issues des mécanismes de contrôle de la Charte africaine par les Etats.
 TITLE AND ABSTRACT IN ENGLISH:
 
 Prevention of statelessness under the African human rights system
 ABSTRACT:
 Although statelessness is not a new phenomenon in Africa, its recent developments are worrisome. This article interrogates the extent to which African human rights norms contributed to prevent statelessness. The analysis is essentially based on the African Charter on Human and Peoples’ Rights and its protocols and on the practice of the African Court and Commission on Human and Peoples’ Rights. The article finds that African human rights norms are not sufficiently equipped to prevent statelessness although the African Court and Commission have played important role in the prevention of statelessness. It recommends the rapid adoption and entry into force of the Protocol to the African Charter on Human and Peoples’ Rights on the Specific Aspects on the Right to a Nationality and the Eradication of Statelessness in Africa. It also recommends that domestic legislation aiming to prevent statelessness should be adopted whilst urging respect of decisions issued by the African Court and Commission on Human and Peoples’ Rights.
Read moreDielectric rod loaded tunable substrate integrated waveguide slot antenna
Abstract This paper presents a novel passive tuning technique to mechanically tune the resonant frequency of a substrate integrated waveguide (SIW) slot antenna, by using cylindrical rods of different dielectric materials in the air holes. A full‐wave 3‐dimensional Electromagnetic simulator software is used to estimate tunability in the resonant frequency of the SIW slot antenna, which is then analysed using its equivalent circuit, and then verified experimentally. Tunability is obtained by changing relative permittivity of dielectric rods. Measurements show good frequency tunability even with a limited number of dielectric rods and gains over 5 dBi. The similarity in the radiation patterns with tuning, demonstrates a good characteristic for tunable antennas. The technique is simple but effective and does not require external direct current bias circuitry, which removes parasitic effects and less power consumption. The low field perturbation of dielectric rods provides better loss performance and a higher Q‐factor over a wider bandwidth. The initial design demonstrates a cost‐effective tuning technique achieving return loss (>10 dB) in the X‐band. This technique is also suitable for practically overcoming the performance deviation due to fabrication inaccuracies and temperature variation.
Read more